Maplight Therapeutics (NASDAQ:MPLT) Upgraded by Wall Street Zen to “Hold” Rating

Wall Street Zen upgraded shares of Maplight Therapeutics (NASDAQ:MPLT) to a hold rating in a research note issued to investors on Wednesday.

Maplight Therapeutics Price Performance

Shares of NASDAQ MPLT opened at $16.00 on Wednesday. Maplight Therapeutics has a 52-week low of $15.00 and a 52-week high of $20.86.

Maplight Therapeutics Company Profile

We are a clinical-stage biopharmaceutical company focused on improving the lives of patients suffering from debilitating central nervous system, or CNS, disorders. We were founded by globally recognized leaders in psychiatry and neuroscience research to address the lack of circuit-specific pharmacotherapies available for patients.